Search

Displaying results 5931 - 5940 of 10000 in total
  1. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  2. Drug

    Alefacept

    go.drugbank.com/drugs/DB00092
    ApprovedWithdrawn

    Produced by CHO cells, mW is 91.4 kD. … Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of

    Categories: CD2-directed LFA-3/Fc Fusion Protein
  3. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. … Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines.

    Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine
  4. Drug

    Technetium Tc-99m oxidronate

    go.drugbank.com/drugs/DB09139
    ApprovedWithdrawn

    [L1138] These complexes are formed by the binding of 99mTc to metal atoms of an organic molecule. … [L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.

  5. Target

    Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1

    go.drugbank.com/bio_entities/BE0008997
    TargetHumans

    S-adenosyl-L-methionine-dependent methyltransferase that mediates mRNA cap1 2'-O-ribose methylation to the 5'-cap structure of mRNAs.

    Polypeptides: Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1Synonyms: Cap methyltransferase 1
  6. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. … [A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene

    Categories: Non COX-2 selective NSAIDS, Analgesics, Non-Narcotic
  7. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]

    Products: SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML, SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.83ML
  8. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed

    Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodySynonyms: Immunoglobulin g1 (262-tyrosine,264-threonine,266-glutamic acid), anti-(human respiratory syncytial virus f protein) (human monoclonal rb1 .gamma.1-chain), disulfide with human monoclonal rb1 .kappa.
  9. Drug

    Glucarpidase

    go.drugbank.com/drugs/DB08898
    ApprovedInvestigational

    [A244750] Glucarpidase is an enzyme that can rapidly hydrolyze methotrexate into its nontoxic metabolites. … [L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.

  10. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis. … [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]

    Synonyms: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s